Asian Journal Of Social Pharmacy

Objective To analyze adverse drug reactions (ADR) caused by sunitinib and provide reference for clinical safety. Methods The case reports of ADR related to sunitinib in six Chinese and English databases from 2006 to 2021 were searched to extract relevant data, and then statistical analysis was performed. Results and Conclusion A total of 147 articles were included, involving 156 cases and 283 adverse events. Adverse reactions occurred at the highest rate after 31 to 180 days of drug administration, and ADR involved organs/systems mainly in blood and lymphatic disorders (17.67%), gastrointestinal disorders (15.55%), and skin and subcutaneous tissue disorders (10.60%). The adverse effects caused by sunitinib involve multiple organs/systems throughout the body. Besides, there are many severe fatal cases. During clinical medication, patients should be monitored regularly, and drugs should be reduced or stopped timely when adverse reactions occur to reduce the risk of clinical medication.